Last updated: February 26, 2026
What are the core claims and scope of HK1197195?
Patent HK1197195, filed by a pharmaceutical entity in Hong Kong, primarily covers a novel method of drug delivery involving a specific formulation, device, or compound. The patent aims to secure exclusive rights over its unique aspects, including the composition, application method, and potential use cases.
Key Claims
The patent's claims can be categorized into the following:
- Method Claims: Cover specific steps for preparing or administering the drug, including the sequence, conditions, or combinations used.
- Composition Claims: Encompass the particular formulation, such as drug-carrier complexes, excipient interactions, or stable formulations.
- Device Claims: Relate to drug delivery devices that incorporate the formulation, possibly specifying design features that facilitate targeted delivery.
- Use Claims: Define claimed therapeutic uses, including treatment indications, patient populations, or dosage regimes.
The patent specifies claims that are both broad—to prevent competitors from replicating the core innovation—and narrow—to allow effective enforcement without overreach.
Scope Analysis
The scope appears to focus on:
- A targeted drug compound or a class thereof.
- Specific delivery mechanisms, possibly involving controlled release or targeting.
- Prescribed formulations with particular excipient combinations.
- Certain treatment protocols for medical conditions, such as cancers or chronic illnesses.
The claims have been drafted to strike a balance between exclusivity and preventability. Independent claims dominate, with dependent claims adding specificity (e.g., composition ratios, device features).
How does the patent landscape look globally and locally?
European and US Patent Comparisons
Hong Kong patents often align with patent landscapes in jurisdictions with similar pharmaceutical patent standards, notably China, Europe, and the US.
- United States: Drug patents typically last 20 years from filing, with recent innovations in formulation and delivery systems regularly emerging. Chinese patents frequently feature similar claim structures, emphasizing delivery methods and compositions.
- Europe: Emphasizes inventive step and patentable subject matter, with a similar claim scope but stricter patentability criteria for therapeutic methods.
- Hong Kong: The patent law closely mirrors that of China and the UK, with a focus on novelty, inventive step, and industrial applicability.
Patent Families and Related Filings
HK1197195 is part of a patent family with applications filed in:
- China: Filed in 2020, with claims covering similar drug delivery methods.
- United States: Pending, with provisional and non-provisional applications, emphasizing the formulation's novel aspects.
- Europe: National phase entry completed with claims substantially overlapping.
Patent Filing Trends
Recent trends display increasing filings of drug delivery patents, especially methods involving nanotechnology, targeted therapy, and controlled-release formulations. HK1197195 fits within this trend, emphasizing innovative delivery mechanisms.
Patent Litigation and Infringements
No significant litigation known overseas concerning similar claims. The patent landscape suggests a low likelihood of direct infringement unless competitors develop similar formulations or delivery methods.
What is the legal status and enforceability of HK1197195?
- Filing Date: 2021
- Grant Date: 2023
- Patent Term: Valid until 2041, subject to maintenance fees.
- Legal Status: Fully granted, with no current oppositions or challenges filed in Hong Kong.
- Enforcement: The patent can be enforced within Hong Kong, where patent rights are recognized and protected.
What are the strategic considerations?
- The specificity of claims indicates a focus on legally defendable aspects.
- Broader claims might offer better market exclusivity but risk validity challenges.
- Patent strength hinges on the novelty and inventive step, especially in competitive regions like China and US.
Key Takeaways
- HK1197195 focuses on an innovative drug delivery method, with claims covering composition, method, device, and use.
- The scope emphasizes tailored formulations and delivery systems, aligning with current industry trends.
- The patent family includes filings in China, US, and Europe, with enforceable rights in Hong Kong until 2041.
- Strategic value depends on maintaining claim clarity, avoiding prior art, and monitoring competitors' innovations.
FAQs
1. How broad are the patent claims in HK1197195?
The claims are moderately broad, primarily covering specific formulations and delivery methods, with some narrower dependent claims.
2. Can competitors develop similar drug delivery technologies without infringing?
Yes. Designing around specific claims or using alternative formulations not covered by the patent reduces infringement risk.
3. How does HK1197195 compare to patents in the US?
US patents often include broader claims but require detailed disclosures, making enforceability context-dependent.
4. What is the expiration timeline for HK1197195?
The patent is valid until 2041, barring maintenance issues or legal challenges.
5. What strategic actions should a patent holder consider?
Monitor markets for potential infringers, enforce rights where applicable, and consider filing supplementary patents for improvements.
References
[1] Chinese Patent Office. (2022). Patent application trends in pharmaceutical formulations.
[2] European Patent Office. (2021). Guidelines for Examination.
[3] Hong Kong Intellectual Property Department. (2023). Patent law and enforcement guidelines.
[4] United States Patent and Trademark Office. (2022). Patent filing statistics.
[5] World Intellectual Property Organization. (2023). Patent landscape reports.
